Skip to content

Released May 11, 2023, after the close

10-Q filed May 11, 2023, 41 days after period end · 0000950170-23-021187

Q1 2023 · 10-Q
Revenue$223.00K−9.7% vs Q1 2022−19.8% vs Q4 2022
Net Income-$13.30MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.25N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$14,227,000N/M
Operating Cash Flow-$12,853,000N/M
Margins · derived
Operating margin-6379.8%+5849.7 pt vs Q1 2022
Net margin-5964.1%+7315.2 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$223.00K$247.00K$7.30M$169.00K
Net Income-$13.30M-$32.80M-$19.40M-$23.30M
EPS Diluted-$0.25-$1.01-$0.66-$1.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR